A5057028241- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Single-cell and spatial transcriptomics
- Cell Image Analysis Techniques
- Immunotherapy and Immune Responses
- Medical Imaging Techniques and Applications
- Cancer Research and Treatments
- Genetic factors in colorectal cancer
- Colorectal Cancer Treatments and Studies
- Ferroptosis and cancer prognosis
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
- interferon and immune responses
- Nanoplatforms for cancer theranostics
University Medical Center Hamburg-Eppendorf
2021-2024
Universität Hamburg
2021-2024
Abstract Microsatellite instability is a strong predictor of response to immune checkpoint therapy and patient outcome in colorectal cancer. Although enrichment distinct T‐cell subpopulations has been determined impact the outcome, little known about underlying changes composition tumor microenvironment. To assess density, composition, degree functional marker expression, spatial interplay subpopulations, 79 microsatellite instable (MSI) 1,045 stable (MSS) cancers were analyzed. A tissue...
Abstract Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate automated immune...
Abstract Background: Microsatellite instability (MSI-h) is a strong biomarker to predict response immune checkpoint therapy and patient’s outcome in colorectal cancer. Although enrichment of distinct T-cell subpopulations, such as type 1 cytotoxic T-cells (Tc1) or helper (Th1), have been identified impact therapy, only little known about the underlying changes composition tumor microenvironment. Material Methods: To assess density, composition, degree functional marker expression, spatial...
Abstract Background: Although there is raising evidence that the density and level of immune checkpoint expression cell subpopulations are in direct contact to tumor cells (intraepithelial) can predict response therapy patient’s outcome, a comprehensive assessment intraepithelial their spatial interplay lacking. Material methods: To comprehensively assess density, expression, 48 expressing leukocyte 46 carcinoma entities, 4740 samples tissue microarray format were stained with 21 antibodies...
Abstract Background: Ki67 is expressed in the G1, S, G2 and M phase of cell cycle. Immunohistochemical determination labeling index (LI) a clinically well-established tool for assessing proliferative activity tumors critical clinical decisions are based on this parameter. Other cycle associated proteins have been evaluated utility much less intensively. This example includes minichromosome maintenance-3 (MCM3) which earlier than Ki67. Design: To evaluate difference potential synergy between...
Abstract Background: The stimulator of interferon genes (STING) is a transmembrane protein expressed on variety cell types including epithelial, inflammatory (lymphocytes and macrophages), endothelial cells. STING expression has been described at variable levels in various tumor where it might enhance anti-tumoral effects the immune system impact angiogenesis. activating targeted therapies are currently evaluated preclinical studies. However, clinical significance cells as compared to...
<div>Abstract<p>Multiplex fluorescence immunohistochemistry (mfIHC) approaches were yet either limited to 6 markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, CD31) in 3098 tumor samples from 44 different carcinoma entities within one week. To...
<div>Abstract<p>Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate...
<div>Abstract<p>Multiplex fluorescence IHC (mfIHC) approaches were yet either limited to six markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, and CD31) in 3,098 tumor samples from 44 different carcinoma entities within one week. To facilitate...
<div>Abstract<p>Multiplex fluorescence immunohistochemistry (mfIHC) approaches were yet either limited to 6 markers or a small tissue size that hampers translational studies on large microarray cohorts. Here we have developed BLEACH&STAIN mfIHC method enabled the simultaneous analysis of 15 biomarkers (PD-L1, PD-1, CTLA-4, panCK, CD68, CD163, CD11c, iNOS, CD3, CD8, CD4, FOXP3, CD20, Ki67, CD31) in 3098 tumor samples from 44 different carcinoma entities within one week. To...
Abstract Immune checkpoint inhibitor (CPI) therapies targeting the PD-1/PD-L1 pathway have shown remarkable results in a rising number of different tumor entities. The likelihood positive response rate to CPIs depends - amongst other factors on PD-L1 expression level cells and infiltrating immune cells. cell types is known impact both function composition microenvironment. However, this process not fully understood. To study intratumoral environment, multiplex fluorescence...